Schizophrenia is a serious psychiatric illness which is experienced by about 1% of
individuals worldwide and has a debilitating impact on perception, cognition, and social …

Emerging evidence from genomics, post-mortem, and preclinical studies point to a potential
dysregulation of molecular signaling at postsynaptic density (PSD) in schizophrenia …

Schizophrenia is a debilitating psychiatric disorder that affects approximately 1% of the
worldLs population at tremendous personal, social, and economic costs. Individuals with …

The postsynaptic density (PSD) contains a complex set of proteins of known relevance to
neuropsychiatric disorders, and schizophrenia specifically. We enriched for this anatomical …

BACKGROUND: Reduced synaptic connectivity in frontal cortex may contribute to
schizophrenia symptoms. While altered messenger RNA (mRNA) and protein expression of …

There are two general models of synaptic dysfunction in schizophrenia. The first relates
synaptic dysfunction to a neurodevelopmental model of the illness (Feinberg 1982–1983 …

Although synaptic loss is thought to be core to the pathophysiology of schizophrenia, the
nature, consistency and magnitude of synaptic protein and mRNA changes has not been …

Schizophrenia is a chronic disease presented with psychotic symptoms, negative symptoms,
impairment in the reward system, and widespread neurocognitive deterioration. Disruption …

There is a growing interest in new molecular targets for antipsychotic therapy. Multiple signal
transduction systems have been recently implicated in the pathophysiology of …

Schizophrenia is one of the most debilitating psychiatric diseases with a lifetime prevalence
of approximately 1%. Although the specific molecular underpinnings of schizophrenia are …